Equities Analysts Offer Predictions for TLX FY2025 Earnings

Equities Analysts Offer Predictions for TLX FY2025 Earnings

Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - William Blair boosted their FY2025 EPS estimates for shares of Telix Pharmaceuticals in a research report issued on Tuesday, July 22nd. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of $0.55 fo

Telix Pharmaceuticals stock drops as SEC probes disclosures tied to cancer treatment

Telix Pharmaceuticals' (TLX) shares fell as much as 16% after the Australian developer of radioactive drugs said it received a subpoena from the U.S. SEC seeking information about disclosures related to its prostate cancer therapeutic candidates.

Telix Shares Drop as SEC Probes Disclosures Tied to Prostate Cancer Drug Pipeline

Telix Pharmaceuticals Ltd. slumped as much as 16%, the most in 21 months, after the Australian developer of radioactive drugs said it received a subpoena from the US Securities and Exchange Commission seeking information about disclosures related to its prostate cancer therapeutic candidates.

Why did the Telix share price just crash 16%?

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is taking a beating today. Shares in the S&P/ASX 200 Index (ASX: XJO) diagnostic and therapeutic product developer closed yesterday trading for $25.12. In earlier trade, shares plunged to $21.00 apiece, down a precipitous 16.4%. After some likely bargain hunting, shares are currently changing hands for $22.41 apiece, down 10.8%. Here's what's got investors hitting their sell buttons today. Tel…